C81.06
Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma, a cancer originating in the lymphatic system. Specifically classified under ICD-10 code C81.06, this form involves the growth of malignant lymphocytes within the intrapelvic lymph nodes. Unlike the more common types of Hodgkin lymphoma, NLPHL tends to follow a slower progression and often affects younger or middle-aged adults. Recognizing the unique features and typical presentation of this form can aid in understanding its diagnosis and potential management options.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal lymphocyte development History of immune system suppression or autoimmune disorders Exposure to certain viruses or environmental factors, though specific causes are not well established Family history of lymphatic or hematologic cancers
Key Symptoms: Painless swelling of lymph nodes in the pelvis, groin, or abdomen Persistent fatigue or weakness Unexplained weight loss Night sweats and fever Abdominal discomfort or pain due to enlarged lymph nodes Itching or skin changes in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosing NLPHL involves a combination of clinical evaluation and diagnostic tests, including: - Physical examination focusing on lymph node regions - Imaging studies such as CT scans or PET scans to identify enlarged lymph nodes within the pelvis - Biopsy: Removing a sample of lymph node tissue for histopathological analysis, which reveals characteristic popcorn-shaped lymphocytes labeled as LP (Lymphocyte Predominant) cells - Immunohistochemistry tests to identify specific markers associated with NLPHL - Blood tests for general health assessment and to check for disease spread
Treatment Protocols: Treatment strategies for NLPHL are tailored to the extent of the disease and individual patient factors. Common approaches include: - **Radiation therapy:** Often used if the disease is localized to the lymph nodes - **Chemotherapy:** Systemic treatment may be recommended for more advanced cases or relapse situations - **Immunotherapy:** Emerging options include monoclonal antibodies targeting specific lymphocyte markers - **Observation:** In some cases with limited disease and minimal symptoms, careful monitoring may be advised The choice of therapy depends on disease stage, location, patient health, and preferences. Long-term follow-up is essential to monitor for disease recurrence or treatment-related effects.
Clinical Advice & FAQs
Billing Guidance
Is C81.06 a billable ICD-10 code?
Yes, C81.06 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.06?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference